Korean bio and pharmaceutical firms are seeking to expand into the U.S. market after the governments of the two countries agreed to expand cooperation in those sectors. The two governments signed 23 MOUs in the bio sector during President Yoon Suk Yeol s state visit to the U.S. last month. The agreements cover cooperation in research and development (R&D), as well as medical devices and digital health. As a result, there is growing optimism of increased momentum in efforts by domestic pharmaceutical and bio companies to enter the U.S.
/PRNewswire/ Aditum Bio, the biotech investment firm cofounded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes.
Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.